Breast cancer treatment in the elderly: Do treatment plans that do not conform to NCCN recommendations lead to worse outcomes?

Presented at the 71st Annual Meeting of the Southwestern Surgical Congress, April 14–17, 2019, Huntington Beach, California, USA
https://doi.org/10.1016/j.amjsurg.2019.12.007Get rights and content

Highlights

  • Breast cancer outcomes were compared in conforming and nonconforming elderly patients.

  • Nonconforming women were older than conforming women (80.5 vs. 77.7 years, P = 0.001).

  • Local recurrence and metastatic disease rates were similar between study groups.

  • Breast cancer related mortality was also similar between study groups.

  • Treatment nonconformity was not associated with poorer outcomes in elderly patients.

Abstract

Background

Aging remains one of the greatest risk factors for development of new breast cancer with more than 30% of breast cancers occurring after the age of 75. Elderly women have been found to not conform with all aspects of treatment recommendations. Our study compared outcomes of elderly breast cancer patients whose treatment did or did not conform to NCCN guidelines.

Methods

A retrospective review was conducted of breast cancer patients over the age of 70. Comparisons were made between patients whose treatment did or did not conform to NCCN guidelines for recurrence, metastatic disease, and breast cancer related deaths.

Results

Patients whose treatment did not conform to NCCN guidelines were older (80.5 vs. 77.7 years, P = 0.001). No significant difference was seen between groups for tumor size, breast cancer type, or nodal status; however, more nonconforming women were ER/PR positive (90.3% vs. 76.6%, P = 0.020). There was no significant difference in local recurrence, metastatic disease, or breast cancer related deaths.

Conclusions

Women whose treatment did not conform to NCCN guidelines were not associated with worse outcomes.

Introduction

Aging remains one of the single greatest risk factors for the development of new onset breast cancer, with approximately one-half of all cases of new onset breast cancer occurring in women older than 65 years of age, and more than 30% occurring after the age of 75.1,2 Elderly patients with breast cancer often present with similar disease characteristics as their younger counterparts. In addition, the cancer stage at diagnosis is typically comparable to those in younger women, although some studies have shown elderly women to have advanced disease at the time of presentation.2 Breast cancer research in the elderly has generally been lacking, and until recently, women over the age of 70 have largely been excluded from breast cancer trials. It was assumed in the past that older cancer patients were unlikely to survive for a sufficient length of time to allow for local or systemic recurrence. However, research has since shown that most breast cancer octogenarians survive greater than six years following their cancer diagnosis with the 5-year survival rate for women 70–79 years of age noted to be 82.4%, and those 80 years and older noted to be 74%.3,4

Studies have also shown that in spite of favorable prognostic factors such as low-grade tumor types, lower incidence of axillary lymph node involvement and vascular invasion, estrogen receptor-positive disease, and less aggressive tumor biology, elderly breast cancer patients often receive less than the standard-of-care when compared to their younger counterparts.1,5 Reasons for under treatment of elderly women may be multifactorial, with physicians limiting treatment for elderly patients secondary to comorbidities and life expectancy. According to Hamaker et al.,6 physicians did not recommend therapy because of older age in 14% and comorbidities in 11%, but 31% of treatment omissions were as a result of patient preference.

Recent research has shown that elderly women who underwent lumpectomies were noncompliant with radiation and hormonal therapy, with noncompliance being even higher in women aged 80 years and older.7

There is a paucity of research evaluating how nonconformity to National Comprehensive Cancer Network (NCCN guidelines) affects outcomes in elderly breast cancer patients. The purpose of this study was to assess whether nonconformity to NCCN treatment guidelines in elderly patients has a negative impact with regards to local recurrence, metastatic disease, and disease-specific survival, compared to patients whose treatment conformed to NCCN guidelines.

Section snippets

Methods

This study was approved for implementation by the Institutional Review Board of Ascension Via Christi Hospitals Wichita, Inc. A retrospective chart review was conducted on women 70 years and older, who underwent treatment for newly diagnosed breast cancer between September 1, 2006 and July 31, 2013. The data was obtained from a single surgeon’s practice and included: age at diagnosis, comorbidities, tumor characteristics, nodal status, treatment received (surgery, hormonal therapy, and/or

Results

Initial records review yielded a total of 186 women older than 70 years of age that were treated for breast cancer. Of those, 7 were excluded due to the presence of metastatic disease at the time of diagnosis, leaving 179 patients for study inclusion (conforming n = 107, and nonconforming n = 72). Nonconforming patients were older than their conforming counterparts by 2.6 years (80.5 vs. 77.7 years, P = 0.001; Table 1). No differences were observed with regard to comorbidities between study

Comments

The incidence of breast cancer significantly increases with age, and in recent years the average age of a woman with newly diagnosed breast cancer has risen to 62 years.9 This data also shows that over 40% of breast cancers occur in women over the age of 65. While the average age at diagnosis has increased, survival is improving. According to SEER, the 5-year survival rate for breast cancer from 2009-20159 was 89.9%, compared to a 5-year survival rate of 87% from 2000 to 2013.4 Despite an

Conclusions

Data from our study showed that nonconformity to NCCN guidelines in elderly patients with breast cancer did not significantly affect their outcome (local recurrence, metastatic disease, and breast cancer related deaths). Nonconformity with hormonal therapy also did not significantly affect patient outcomes. Larger studies are required to confirm these findings. In addition, more research may be required to verify whether hormonal therapy is required in elderly patients, as this could

References (11)

There are more references available in the full text version of this article.

Cited by (11)

  • Development and Validation a Survival Prediction Model and a Risk Stratification for Elderly Locally Advanced Breast Cancer

    2022, Clinical Breast Cancer
    Citation Excerpt :

    To date, few researchers have focused on the long-term prognosis of LABC, in part because of the small proportion of such patients and the difficulty of following up on their poor prognosis.5,7-9 Second, it has been noted that the elderly is more likely to develop LABC and age itself is a survival disadvantage, so overall survival (OS) tends to be worse in the elderly with LABC.7,10 This is because advanced age meant that their physical condition, self-care and compliance were less likely to benefit from multidisciplinary treatment or clinical trials.9

  • Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study

    2021, European Journal of Surgical Oncology
    Citation Excerpt :

    Breast cancer (BC) risk and the incidence of comorbidities rise with age [1]. The risk of developing BC increases with age with half of all cases of new onset breast cancer occurring in women older than 65 years of age, and more than 30% occurring after the age of 75 years [2]. Breast surgery (breast conserving surgery or mastectomy) is a safe procedure with clear oncological benefit and it is recommended for the great majority of elderly (defined as those aged 70 years or older) patients [3].

  • Recent Advances in Cancer Diagnostics and Therapy: A Nanobased Approach

    2022, Recent Advances in Cancer Diagnostics and Therapy: A Nanobased Approach
View all citing articles on Scopus
View full text